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SPECIAL ARTICLE

Effects of antipsychotics, antidepressants and mood
stabilizers on risk for physical diseases in people with
schizophrenia, depression and bipolar disorder
CHRISTOPH U. CORRELL1-4, JOHAN DETRAUX5, JAN DE LEPELEIRE6, MARC DE HERT5
1
Department of Psychiatry, Zucker Hillside Hospital, North Shore - Long Island Jewish Health System, Glen Oaks, New York, NY, USA; 2Department of Psychiatry and Molecular Medicine, Hofstra North Shore LIJ School of Medicine, Hempstead, New York, NY, USA; 3Psychiatric Neuroscience Center of Excellence, Feinstein Institute for Medical Research, Manhasset, New York, NY, USA; 4Department of Psychiatry and Behavioral Sciences, Albert Einstein College of Medicine,
Bronx, New York, NY, USA; 5Department of Neurosciences, Catholic University Leuven, B-3070 Kortenberg, Belgium; 6Department of Public Health and Primary Care, University of Leuven, B-3000 Leuven, Belgium

People with severe mental illness have a considerably shorter lifespan than the general population. This excess mortality is mainly due to
physical illness. Next to mental illness-related factors, unhealthy lifestyle, and disparities in health care access and utilization, psychotropic
medications can contribute to the risk of physical morbidity and mortality. We systematically reviewed the effects of antipsychotics, antidepressants and mood stabilizers on physical health outcomes in people with schizophrenia, depression and bipolar disorder. Updating and
expanding our prior systematic review published in this journal, we searched MEDLINE (November 2009 - November 2014), combining the
MeSH terms of major physical disease categories (and/or relevant diseases within these categories) with schizophrenia, major depressive disorder and bipolar disorder, and the three major psychotropic classes which received regulatory approval for these disorders, i.e., antipsychotics, antidepressants and mood stabilizers. We gave precedence to results from (systematic) reviews and meta-analyses wherever possible.
Antipsychotics, and to a more restricted degree antidepressants and mood stabilizers, are associated with an increased risk for several physical diseases, including obesity, dyslipidemia, diabetes mellitus, thyroid disorders, hyponatremia; cardiovascular, respiratory tract, gastrointestinal, haematological, musculoskeletal and renal diseases, as well as movement and seizure disorders. Higher dosages, polypharmacy, and
treatment of vulnerable (e.g., old or young) individuals are associated with greater absolute (elderly) and relative (youth) risk for most of
these physical diseases. To what degree medication-specific and patient-specific risk factors interact, and how adverse outcomes can be minimized, allowing patients to derive maximum benefits from these medications, requires adequate clinical attention and further research.
Key words: Physical illness, cardiovascular, metabolic, endocrine, gastrointestinal, respiratory, schizophrenia, bipolar disorder, depression,
antipsychotics, antidepressants, mood stabilizers
(World Psychiatry 2015;14:119–136)

People with severe mental illness (SMI), particularly schizophrenia, bipolar disorder and major depressive disorder,
have an average mortality rate that is 2-3 times higher than
the general population (1-3), corresponding to a 10-25 year
shortened life expectancy (2-9). The most common causes
of death in people with SMI are physical diseases (10).
Mental illness-related factors, unhealthy lifestyle choices,
as well as disparities, not only in health care access and utilization, but also in health care provision, contribute to the
poorer physical health outcomes in people with SMI (11).
However, the use of psychotropic medications can further
increase the risk of physical complications/disorders.
Thorough knowledge about the effects of frequently used
psychotropic medications – antipsychotics, antidepressants
and mood stabilizers – on physical health in people with
SMI can inform better treatment choices and/or strategies.
Updating and expanding our prior review published in
this journal (11), we systematically searched MEDLINE
(November 2009 - November 2014) for epidemiological,
morbidity and mortality data combining the MeSH terms of
major physical disease categories and/or relevant diseases
within these categories (Table 1) with schizophrenia, major
depressive disorder and bipolar disorder, and the three
major psychotropic classes which received regulatory approval for these psychiatric disorders, i.e., antipsychotics,

antidepressants and mood stabilizers. While psychotropic
medications can potentially increase the risk of many physical diseases, we focused on a selected number of diseases.
We further restricted our search to pertinent English-language
(systematic) reviews and meta-analyses, although for certain
physical diseases relevant individual studies were selected.
The MEDLINE searches yielded 13,477 hits (Table 1).
Below, we summarize the findings concerning the relationship of antipsychotics, antidepressants and mood stabilizers
to each physical illness/domain.

NUTRITIONAL AND METABOLIC DISEASES
Obesity
People with SMI are, compared to the general population, at increased risk for being overweight and obese (1215). The likelihood of being obese is increased 2.8-4.4 fold
in patients with schizophrenia and 1.2-1.7 fold in those with
major depression or bipolar disorder (16-22).
Weight gain – commonly assessed as body weight change,
change in body mass index, or clinically relevant (7%)
weight change from baseline (23,24) – is a well-established
side effect of antipsychotics during the acute and maintenance
119

Table 1 MEDLINE search results: disease category

(1SMI, 1 psychotropic)

Nutritional and metabolic diseases: 1,958 hits (358 reviews)
Obesity: 1,550 hits (266 reviews)
Dyslipidemia: 408 hits (92 reviews)
Endocrine system diseases: 1,709 hits (324 reviews)
Diabetes mellitus/diabetic ketoacidosis: 1,305 hits (256 reviews)
Thyroid disorders/hyponatremia/SIADH: 404 hits (68 reviews)
Cardiovascular diseases: 1,394 hits (211 reviews)
Coronary heart disease/sudden cardiac death: 617 hits (85 reviews)
Cerebrovascular disease: 777 hits (126 reviews)
Hypertension/myocarditis: 965 hits (165 reviews)
Respiratory tract diseases
Pneumonia: 108 hits (11 reviews)
Gastrointestinal diseases
Liver diseases/constipation: 672 hits (150 reviews)
Neoplasms
Cancer: 2,387 hits (396 reviews)
Muscoloskeletal diseases
Osteoporosis: 163 hits (49 reviews)
Haematologic diseases: 364 hits (40 reviews)
Other diseases: 4,121 hits (890 reviews)
SMI – severe mental illness, SIADH – syndrome of inadequate antidiuretic
hormone secretion

treatment of patients with schizophrenia, affecting 15 to 72%
of these patients (11).
There is, however, a hierarchy for risk of weight gain
among antipsychotics, that has been confirmed in different
studies and meta-analyses (11,23-33). Weight gain is greatest with the second-generation antipsychotics (SGAs)
clozapine and olanzapine, while quetiapine, risperidone,
paliperidone and iloperidone have an intermediate risk. Aripiprazole, amisulpride, ziprasidone, asenapine and lurasidone have less or little effect on body weight (11) (Table 2),
although observed effects depend on the degree of prior
treatment exposure (30). In children and adolescents (<18
years old), roughly the same hierarchy for risk of weight
gain with these agents has been identified (23,34-36), yet at
a higher level, likely due to less prior antipsychotic exposure
(30). Among the first-generation antipsychotics (FGAs), the
so-called low-potency agents, such as chlorpromazine and
thioridazine, have higher weight gain potential than the
high-potency drugs, such as haloperidol (11,30).
No antipsychotic, however, should be considered truly
weight neutral, as the proportion of individuals experiencing significant weight gain is greater with any SGA than
120

with placebo (11,31). Antipsychotic-na€ıve or first-episode
patients are more vulnerable to weight gain, as all antipsychotics have been found to cause significant weight gain
in these patients (24). Moreover, antipsychotics have
been found to produce more severe weight gain in these
patients compared to those with chronic schizophrenia (37).
Generally, weight gain with antipsychotics is rapid during
the first few weeks, slows gradually, and often reaches a plateau within one year (23). Results indicate that the first year
of antipsychotic treatment is a critical period for weight gain
and metabolic abnormalities (38), as initial rapid weight
gain is a good indicator for long-term weight gain and obesity (23,39). According to a recent meta-analysis (24), almost
all antipsychotics show a degree of weight gain after prolonged use, except for amisulpride, aripiprazole and ziprasidone. This meta-analysis also documented that switching
subjects to metabolically more neutral compounds may not
result in weight loss in all cases.
Antidepressants, such as amitriptyline and mirtazapine,
and mood stabilizers, such as lithium and valproate, have
also been associated with weight gain (23,40,41) (Table 2).
However, weight gain is generally more modest or mild with
antidepressants and mood stabilizers, and differences between antidepressants are modest (40).
Clinical and animal study data suggest that increasing
appetite and food intake, as well as delayed satiety signaling,
are key behavioral changes to antipsychotic-induced weight
gain/obesity (24,39,42). Antagonism at 5-HT2C and H1
receptors seems involved in antipsychotic-induced weight
gain. Among antipsychotics, clozapine and olanzapine,
which have the highest weight gain/obesity risk, also have
the highest affinities for 5-HT2C and H1 receptors (39).
There are marked individual variations in weight gain,
irrespective of prescribed antipsychotic (39): some subjects
lose weight, others maintain or gain weight with the same
agent (24). Although (partial) non-adherence can be a confounder, this observation, together with the results from
monozygotic twin and sibling studies, suggests that genetic
factors play an important role in medication-induced weight
gain (43-45), with estimates as high as 60-80% for antipsychotic-related weight gain (46).

Dyslipidemia
Antipsychotics have been associated with lipid abnormalities to relevant degrees (11,30) (Table 2). Adverse
effects on triglycerides and cholesterol occur early and may
even precede weight gain, pointing to weight-independent,
molecular effects in addition to weight-related ones (30).
Compared to age- and sex-matched general population
cohorts, metabolic syndrome criteria for elevated triglycerides (OR 5 2.73, 95% CI: 1.95-3.83) and decreased highdensity lipoprotein (HDL) cholesterol (OR 5 2.35, 95% CI:
1.78-3.10) were more commonly met in patients with
schizophrenia (17). Moreover, in chronic antipsychotic
World Psychiatry 14:2 - June 2015

Table 2 Adverse effects of antipsychotics, antidepressants and mood stabilizers on specific physical health outcomes
Physical disease/condition

Antipsychotics

Antidepressants

Mood stabilizers

0/1 (haloperidol, lurasidone,
ziprasidone, aripiprazole)
to 111 (clozapine,
olanzapine, low potency FGAs)

2 (bupropion) to 1 (mirtazapine,
paroxetine, TCAs)

0 (lamotrigine) to 11
(valproate, lithium)

1 to 11

0 to 1 (if weight gain)

2 (valproate: cholesterol) to 1

0/1 (haloperidol, lurasidone,
ziprasidone, aripiprazole)
to 111 (clozapine and olanzapine > low and
mid potency FGAs)

0 to 1

0 to 11 (valproate)

Thyroid disorders

0

0

0 to 11 (lithium)

Hyponatremia/SIADH

1

1 to 11 (SSRIs)

0 to 1

0 to 11

0 to 1 (venlafaxine)

0

Nutritional and metabolic diseases
Obesity

Dyslipidemia
Endocrine system diseases
Diabetes

Cardiovascular diseases
Hypertension
Coronary heart disease and stroke

1 to 11

0 to 1

0 to 1

0 to 1 (clozapine)

0

0

0 to 1 (thioridazine>sertindole
> ziprasidone)

0 to 1 ?

0

1 to 11 (clozapine)

0

2 (lithium) to 0

Constipation

0 to 11 (clozapine)

0 to 1 (TCAs)

0

Liver dysfunction

0 to 11 (often early
and transient)

1

0 to 11 (valproate >
carbamazepine)

Myocarditis
QTc prolongation/
sudden cardiac death
Respiratory tract diseases
Pneumonia
Gastrointestinal diseases

Neoplasms
Breast cancer

0 to 1 ?

0

0

Prolactinoma

0?

0

0

0 to 1 (prolactin-raising
antipsychotics)

1

2 (lithium) to 0

1 to 111 (clozapine)

0 to 1

0 to 11 (carbamazepine)

0

0

0 to 11 (valproate)

Musculoskeletal diseases
Osteoporosis/fractures

Hematologic diseases
Leucocytopenia/agranulocytosis
Thrombocytopenia
Other physical diseases
Kidney diseases
Movement disorders
Seizure disorders

0

0

0 to 11 (lithium)

1 to 111

0 to 1

0 to 1

1 to 11 (clozapine)

0 to 1 (TCAs > bupropion)

2 to 1 (lithium toxicity)

2 5 reduction; 0 5 likely/generally no effect; 1 5 some effect; 11 5 moderate effect; 111 5 marked effect, ? 5 questionable
SIADH – syndrome of inadequate antidiuretic hormone secretion, FGAs – first-generation antipsychotics, SSRIs – selective serotonin reuptake inhibitors, TCAs –
tricyclic antidepressants

treated patients, compared to first-episode or untreated
patients with schizophrenia, metabolic syndrome criteria
were more commonly met for elevated triglycerides (19.6%

and 16.9% vs. 41.1%) and low HDL cholesterol (21.9% and
20.4% vs. 44.7%) (17). An elevated risk for meeting the triglyceride and HDL cholesterol criteria for metabolic
121

syndrome was also found in patients with depression (22)
and bipolar disorder (47), with higher metabolic syndrome
risk in populations receiving antipsychotics.
Although some antidepressants have been associated
with weight gain (23,41), which is a risk factor for lipid
abnormalities, data on adverse lipid effects of these medications remain scarce, and most antidepressants have not
been associated with dyslipidemia (48) (Table 2).
Among mood stabilizers, lithium has not been associated
with relevant lipid abnormalities (49), although lithiuminduced hypothyroidism can lead to weight gain and
changes in lipid profile (50). Valproate has been associated
with reductions in total and low-density lipoprotein (LDL)
cholesterol in patients with schizophrenia (51) and bipolar
disorder (52), despite its association with weight gain,
increased triglycerides and glucose, and insulin abnormalities (53) (Table 2).

ENDOCRINE SYSTEM DISEASES
Diabetes mellitus
Evidence suggests that the prevalence of type 2 diabetes
mellitus (DM) in people with schizophrenia, bipolar disorder and schizoaffective disorder is 2-3 fold higher than in
the general population (9,16,25,39,54,55). Two meta-analyses found overall prevalences of DM in people with multiepisode psychosis to be 9.5% (N 5 116,751) (16) and 12.8%
(N 5 2,098) (56), respectively, nearly twice as high as in
the general population (9). The risk of type 2 DM in people
with (major) depression or depressive symptoms is 1.2-2.6
times higher than in those without depression (11,57). The
age of onset of DM in individuals with a SMI seems to be
about 10-20 years earlier than in the general population
(58,59).
An association, albeit of uncertain magnitude, seems to
exist between antipsychotics and DM, affecting about 12%
of people receiving these medications (9). Recently, metaanalyses (16,56) showed that the prevalence of DM is not
appreciably increased in drug-na€ıve patients during the first
episode of psychosis once control groups are age-matched.
The majority of studies suggest that metabolic abnormalities
accumulate rapidly after the initiation of treatment (9,30).
Although a former meta-analysis showed that SGAs
seem to have a stronger diabetogenic risk than FGAs, the
risk being 1.3 fold higher in people with schizophrenia taking the former compared with those receiving the latter
medications (60), a more recent meta-analysis indicated
that, at the moment, evidence is still insufficient to draw
firm conclusions about the relative risk of SGAs and FGAs
(61). However, this uncertainty may well be due to the fact
that neither of the two classes is homogeneous regarding
cardiometabolic risk. Several studies suggest that the differing weight gain liability of SGAs contribute to the differing
relative risks (RRs) of DM with these agents: specifically,
122

olanzapine and clozapine, and to a lesser extent quetiapine
and risperidone, were shown to be associated with an increased risk of glucose dysregulation or DM in people who
have schizophrenia or bipolar disorder (28,62) (Table 2).
Nielsen et al (63) showed DM development in firstepisode schizophrenia patients initially treated with olanzapine (hazard ratio, HR 5 1.41) and mid-potency FGAs
(HR 5 1.60). During longer-term treatment and adjusting
for follow-up duration, DM was associated with lowpotency FGAs (OR 5 1.45), olanzapine (OR 5 1.57) and
clozapine (OR 5 2.31). Fleischhacker et al (64) found, in
first-episode schizophrenia patients, newly diagnosed cases
of DM with olanzapine and amisulpride during a 52-week
treatment period.
Antipsychotics should be used with caution in children
and youth (65). A recent study (66) found a 3-fold increased
risk of DM in children and youth (the most frequently
recorded psychiatric diagnoses were mood disorders, attention-deficit/hyperactivity disorder and conduct disorder)
who had recently initiated antipsychotic treatment (HR 5
3.03, 95% CI: 1.73-5.32), compared to those receiving other
psychotropic medications. The risk was already increased
within the first treatment year (HR 5 2.49, 95% CI: 1.274.88), increased further with cumulative dose, and remained
elevated one year after antipsychotic discontinuation (HR 5
2.57; 95% CI: 1.34-4.91) (67).
Antipsychotics may induce DM independent of weight
gain and adiposity (39,42). Thus, a model in which
antipsychotic-induced DM is solely due to obesogenic effects
is an oversimplification (42). These medications appear to
contribute to DM both indirectly, by inducing weight gain,
and directly, by promoting insulin resistance. M3 receptors
play a crucial role in the regulation of insulin secretion
through both peripheral and central cholinergic pathways
(39). Therefore, DM induced by SGAs may be partly due to
the blockade of central and peripheral M3 receptors. Olanzapine and clozapine, the SGAs with the highest risk to
induce DM, also possess the highest M3 receptor-binding
affinity (40). M3 blockade may lead to an initial disruption of
insulin secretion and glucose homeostasis that can progressively lead to insulin resistance and DM during chronic
treatment (67).
The literature is still inconclusive on a possible association between antidepressants and DM (23,68-71). Several
reports (68,72-75) suggest that the (concurrent) use of
(certain) antidepressants is associated with an increased
risk of glucose dysregulation or DM; others do not (76,77)
(Table 2).
A recent meta-analysis (78) found that antidepressants
increased the likelihood of new-onset DM (OR 5 1.50, 95%
CI: 1.08-2.10; HR 5 1.19, 95% CI: 1.08-1.32). However,
because only observational studies were included in this
analysis, a causal relationship could not be established
(71,78). Long-term randomized controlled and prospective
studies are needed to confirm a possible cause-effect relationship. Another problem is that (major) depression may
World Psychiatry 14:2 - June 2015

act as a confounding variable in the relationship between
antidepressants and DM risk: antidepressants may have an
impact on mental illness-related factors relevant to the risk
for DM, such as physical activity and diet (71,79).
Nevertheless, there are indications that an increased risk
of DM is associated with the concurrent use of tricyclic antidepressants and selective serotonin reuptake inhibitors
(SSRIs) (OR 5 1.89) (80), the long-term use of either tricyclic antidepressants (incidence rate ratio, IRR 5 1.77) or
SSRIs (IRR 5 2.06) in at least moderate daily doses (81),
and the use of antidepressants in high-risk patients (82).
Some reports (57) also indicated that the use of mood stabilizers is associated with DM (OR 5 1.64) in patients with
major depression. Indeed, certain mood stabilizers, especially valproate, have been associated with an elevated risk
for the development of insulin resistance (83) (Table 2).

Diabetic ketoacidosis
Although diabetic ketoacidosis (DKA), a potentially fatal
condition (84), occurs most often in patients with type 1 DM
(85), it may be the first obvious manifestation of type 2 DM.
Physical symptoms include: increased thirst (polydipsia) and
urination (polyuria), excessive appetite (polyphagia), nausea,
abdominal pain and vomiting, dehydration, Kussmaul
breathing, acetone (“fruity apple-like”) breath, weakness or
lethargy, confusion and alerted consciousness (85).
The incidence of DM presenting as DKA is, compared to
the general population, nearly 10-fold higher in patients
with schizophrenia (86). Cases of DKA in patients not previously known to be diabetic, including several fatalities,
have been associated with SGA treatment initiation (54,86).
While the underlying mechanisms are not well understood,
antipsychotic-related DKA can occur soon after treatment
onset and in the absence of weight gain (over one third of
cases presented with either no weight gain or even weight
loss) (85).
DKA can occur with almost all SGAs. However, at least
half of the reports involve individuals on polypharmacy,
complicating the risk attribution to a specific antipsychotic
(85). The greatest number of DKA cases has been observed
with clozapine and olanzapine. However, cases have also
been reported with quetiapine, risperidone, and even with
aripiprazole and ziprasidone (85,87), although order or
channelling effects (i.e., shifting high-risk patients to lower
risk agents) cannot be excluded.
Although DKA remains a rare adverse effect of SGAs,
clinicians must remain vigilant, given its acute onset and
potential lethality (85).

Hypothyroidism and hyperparathyroidism
Hypothyroidism is a common adverse effect of lithium,
warranting continued monitoring (Table 2). A recent sys-

tematic review (40) concluded that, compared to placebo,
lithium is associated with increased thyroid stimulating hormone (TSH) levels (14.00 iU/mL, 95% CI: 3.9-4.1) and
clinical hypothyroidism (OR 5 5.78, 95% CI: 2.00-16.67).
In addition, lithium can produce adverse effects on the
parathyroid gland. Compared with placebo, lithium was
associated with increased parathyroid hormone (17.32 pg/
mL, 95% CI: 3.42-11.23) and blood calcium (1009 mmol/
L, 95% CI: 0.02-0.17), but effects are generally mild (40).
Although quetiapine has been associated with mild T4
elevations, TSH levels were within normal limits and patients remained euthyroid (88).
Other antipsychotics, antidepressants, valproate and carbamazepine do not seem to affect thyroid or parathyroid
functioning (Table 2).

Syndrome of inappropriate antidiuretic hormone
secretion and hyponatremia
Antipsychotics appear to be associated with an increased
prevalence of hyponatremia (89,90), which is often associated with polydipsia (Table 2).
Antidepressants, especially SSRIs, have been associated
with the syndrome of inappropriate antidiuretic hormone
secretion and with hyponatremia (91) (Table 2). In a recent
systematic review (92), that was limited by variations in
study designs, populations, and utilized thresholds, the incidence of hyponatremia diverged between 0.06% and 40%
for SSRIs and between 0.08% and 70% for venlafaxine. Incidences for mirtazapine and tricyclic antidepressants were
lower, and ORs for SSRIs (1.5-21.6) were consistently
higher than for tricyclic antidepressants (1.1-4.9), but much
less evidence was available for non-SSRI antidepressants.
Identified patient risk factors included older age (OR 5 6.3)
and concomitant use of (thiazide) diuretics (OR 5 11.213.5) (92). Carbamazepine and valproate have been associated with hyponatremia in case reports.
Based on the above, electrolytes should be checked in
patients on antipsychotics, antidepressants and/or mood
stabilizers with otherwise unexplained physical or mental
state deterioration (Table 2).

CARDIOVASCULAR DISEASES
Hypertension
Although antipsychotics increase body weight and are
associated with obesity, their effect on blood pressure is less
pronounced than expected. This has likely to do with their
alpha-1 blocking effects (93), which can lower blood pressure. Nevertheless, hypertension criteria for metabolic
syndrome are more commonly met in patients with schizophrenia than in the general population (OR 5 1.36, 95% CI:
1.21-1.53) (16), as well as in chronic patients with schizo123

phrenia receiving antipsychotics (39.7%) than in firstepisode (30.4%) or untreated patients (24.3%) (56). Elevated risk for meeting the hypertension criterion for metabolic
syndrome was also found in patients with depression (22)
and bipolar disorder (47), with higher metabolic syndrome
risk in populations receiving antipsychotics (Table 2).
Among antidepressants, venlafaxine is the one most frequently associated with increase in blood pressure (94),
while mirtazapine has been found to be associated with
hypertension less than tricyclic antidepressants (95) (Table
2). Generally, mood stabilizers do not affect blood pressure,
unless chronic renal failure induced by lithium affects volume distribution (Table 2).

Coronary heart disease and stroke
The preponderance of evidence suggests that patients
with schizophrenia, bipolar disorder and major depression
are at significantly higher risk for cardiovascular morbidity
and mortality than their counterparts in the general population (1,5,6,11,96-99). The risk is approximately 1.5 to 3-fold
increased in patients with schizophrenia and bipolar disorder, and on average 1.5-fold increased in those with major
depression. Moreover, cardiovascular diseases are the commonest cause of death in patients with SMI (100,101), with
risks 10-fold higher than suicide (102). The literature on
antipsychotic-related cardiovascular outcomes in patients
with a SMI is sparse. Moreover, data are conflicting.
Although some studies (103,104) reported a higher risk
of cerebrovascular diseases in patients using antipsychotics,
others (105) did not (Table 2). In case-control studies with
elderly patients, the probability of cerebrovascular accidents in antipsychotic users, compared with non-users, was
approximately 1.3- to 2-fold greater (106). The risk of stroke
is highest during the first weeks of treatment (104,106). A
recent meta-analysis of 20 observational cohort studies
found that older adults (65 years) using FGAs were not at
a statistically significantly increased higher risk (RR 5 1.4;
95% CI: 0.81-1.91) for stroke, as compared to SGA users
(107).
Few studies have looked at the association between antipsychotics and myocardial infarction, which remains controversial because of heterogeneous clinical settings and
methodological approaches (108,109). Some found an increased risk of myocardial infarction in older patients (66
years) with or without dementia (110,111) or patients with
SMI (109,112) using antipsychotics compared to control
subjects (RR 5 1.15-6.2) (110,111). In the study by Lin et al
(109), carried out in a large sample of patients with schizophrenia, mood disorders or dementia, the adjusted OR of
acute myocardial infarction risk was 2.52 (95% CI: 2.372.68) for any antipsychotic, 2.32 (95% CI: 2.17-2.47) for
FGAs, and 2.74 (95% CI: 2.49-3.02) for SGAs. A recent
meta-analysis found that older adults (65 years) using
FGAs were at higher risk for myocardial infarction (RR 5
124

1.2; 95% CI: 1.16-1.23) compared to SGA users (107).
However, several other studies (e.g., 112) found no significant association between the risk of myocardial infarction
and antipsychotic exposure.
The risk for cardiovascular events varies with the individual
SGAs. This risk seems to be lowest with aripiprazole and
ziprasidone (113-115). Considering FGAs, a nationwide,
register-based, five-year follow-up study of all patients presenting with first onset of schizophrenia found an increased
likelihood for cardiovascular deaths among users of levomepromazine (OR 5 2.68; 95% CI:1.37-5.25, p 5 0.004) (116).
Data on the comparative acute cardiovascular safety of
SGAs in younger adults are limited. In a recent large nationwide register-based cohort study (N 5 48,625) (117), the risk
of major cardiovascular events (cardiovascular mortality,
acute coronary syndrome or ischemic stroke) in non-elderly
(18-64 years) psychiatric outpatients was similar with risperidone, olanzapine and quetiapine within one year of treatment initiation. In another recent commercial U.S. claims
database inception cohort study of 284,234 non-elderly
adults aged 18-65 years (118), individuals within one year of
exposure to SGAs showed a higher risk of essential hypertension (adjusted HR, AHR 5 1.16, 95% CI: 1.12-1.21), DM
(AHR 5 1.43, CI: 1.33-1.53), hypertensive heart disease
(AHR 5 1.34, CI: 1.10-1.63), stroke (AHR 5 1.46, CI: 1.221.75), coronary artery disease (AHR 5 1.17, CI: 1.05-1.30),
and hyperlipidemia (AHR 5 1.12, CI: 1.07-1.17) than those
exposed to antidepressants.
Compared to obese individuals without a SMI, obese
patients with SMI have a significantly higher cardiovascular
risk (119). This raises the possibility that, in addition to
weight gain and obesity-related mechanisms, a direct effect
of antipsychotics on cardiovascular risk may exist. For
example, autonomic nervous system dysfunction triggered
by schizophrenia may be exacerbated by antipsychotic
treatment through blockade of peripheral dopamine receptors, increasing sympathetic activity (120). A direct effect of
antipsychotics on insulin resistance, causing glucose intolerance, is another possible mechanism contributing to the
increased risk of cardiovascular diseases (121).
The potential cardiovascular effects of tricyclic antidepressants are well known. They can cause orthostatic
hypotension, slowed cardiac conduction, and increased
heart rate, and are therefore best avoided in patients with
pre-existing cardiovascular disease (122). SSRIs appear to
have a better cardiovascular safety (123,124) (Table 2).
Nevertheless, in patients with high risk factors, SSRIs (i.e.,
citalopram) (125,126) may be associated with (modest)
QTc prolongation. Serotonin-norepinephrine reuptake
inhibitors (SNRIs) are associated with a small, but
increased incidence of cardiovascular adverse events
(hypertension, tachycardia and orthostatic hypotension),
while at therapeutic doses they do not seem to cause QTc
prolongation (122). Although lithium can have some cardiac conduction effects, in general, it can be used safely in
patients with cardiac disease (123) (Table 2).
World Psychiatry 14:2 - June 2015

Myocarditis
Myocarditis is a potential risk of clozapine treatment,
occurring often early in treatment and in young male
patients (127). Therefore, routine electrocardiographic monitoring for the first four weeks, and discontinuation of clozapine in the presence of myocarditis, may assist to prevent
fatalities (128). However, case reports suggest that rechallenge
with clozapine using slow titration may be successful in the
majority of reported cases (129).

Sudden cardiac death
Patients with schizophrenia have been reported to be 2-4
times more likely to experience sudden cardiac death (SCD)
than the general population (130,131). Although reasons
for this increased risk remain unclear, individual susceptibility (e.g., underlying coronary artery disease (101) and
higher prevalence of Brugada electrocardiographic abnormalities (131)) seems to be a relevant factor. Additional
important risk factors include unhealthy lifestyle factors
and psychotropic medications.
The association between SCD and specific psychotropic
drugs has been explained by a lengthening of ventricular
repolarization (QTc prolongation), predisposing the patient
to life-threatening ventricular tachyarrhythmias (i.e., torsades de pointes, TdPs) (132). There is a consensus that QTc
values >500 msec, or an absolute increase of 60 msec
compared with drug-free baseline, puts patients at significant risk of TdPs and SCD (126,133). However, although a
link exists between QTc and TdPs, this is neither linear, nor
straightforward (126). Indeed, TdPs can occur at therapeutic doses of antipsychotics or antidepressants with a QTc
interval <500 ms (134).
Patients using FGAs or SGAs have an increased risk of
SCD compared to non-users with or without a psychiatric
illness, with ratios ranging from 1.5 to 5.8, depending on the
type of antipsychotic and restrictiveness of the SCD definition (11,131,135,136). The largest study to date (459,614
incident antipsychotic users) reported a SCD incidence of
3.4 per 1,000 person-years (137). Antipsychotics with a
greater risk of QTc prolongation include thioridazine
(greatest risk), pimozide, droperidol, mesoridazine, and i.v.
haloperidol (total cumulative dose > 2 mg) among FGAs
(126,133), and sertindole, amisulpride and ziprasidone
among SGAs (32,133). QTc prolongation with lurasidone
and aripiprazole is judged to be clinically insignificant
(32,133). QTc prolongation associated with asenapine and
iloperidone is comparable to that associated with risperidone, olanzapine and quetiapine (32,133) (Table 2).
According to a recent meta-analysis, SSRIs are, compared to placebo, associated with a statistically significant
(but clinically insignificant for most patients) dose-dependent increase in the QTc interval (16.10 milliseconds; 95%
CI: 3.47-8.73, p<0.001) (125). The highest effect seems to

be associated with citalopram (138). Tricyclic antidepressants prolong the QTc interval to a greater extent than
SSRIs by a factor of more than 2 (125).
Studies linking antipsychotics and antidepressants with
an increased SCD risk suggest a dose-dependent relationship (135,139).
Cases of TdPs have been reported with antipsychotics,
tricyclic antidepressants and SSRIs. Using the FDA Adverse
Event Reporting System (FAERS) data, the Arrhythmogenic
Potential of Drugs (ARITMO) project (140,141) classified,
next to ziprasidone, five other SGAs (amisulpride, clozapine, olanzapine, quetiapine and risperidone) as having a
very strong torsadogenic signal. However, these antipsychotics (with the exception of amisulpride and possibly
quetiapine) have, in general, been associated with a QTc
prolongation potential of questionable clinical concern
(133). SSRI-associated TdP is a very rare event: only very
few cases have been reported (142). However, adding SSRIs
to SGAs may, although also very rarely, contribute to TdPs
(143). There are no reported cases of lithium-induced TdPs
(139).
Notably, coronary heart disease underlies the majority of
SCD (144). A recent recommendation concludes that it is
not mandatory to perform electrocardiogram monitoring as
a prerequisite to initiating antipsychotic treatment in the
absence of cardiac risk factors, unless the prescribed antipsychotic has been established to have an increased risk of
TdP and SCD (133) (Table 2).

RESPIRATORY TRACT DISEASES
Pneumonia
One century ago, respiratory diseases, such as pneumonia and tuberculosis, accounted for the majority of deaths
amongst people with SMI who lived in institutions (145).
Today, they are still more prevalent in these individuals
compared to the general population, and among the most
common causes of death (146-149).
Not only having a SMI, but also the use of psychotropics
is a risk factor for respiratory tract diseases. A dosedependent increased risk for pneumonia is associated with
current use of SGAs in patients with schizophrenia (adjusted RR, ARR 5 1.69, 95% CI: 1.43-2.01 vs. non-users)
(150,151) and bipolar disorder (ARR 5 2.07, 95% CI: 1.582.71 vs. non-users) (152). Similarly, the current use of SGAs
and FGAs in elderly patients without a SMI seems to be
associated with a dose-dependent increase in the risk for
pneumonia (153-157).
In patients with schizophrenia, particularly the current
use of clozapine is associated with an elevated and dosedependent risk of pneumonia (ARR 5 3.18, 95% CI: 2.623.86, p<0.001), while this risk is moderate for olanzapine,
quetiapine and risperidone (ARR between 1.32 and 1.83,
p<0.001), compared to patients not currently using anti125

psychotics (150) (Table 2). In patients with bipolar disorder, the current use of clozapine (ARR 5 2.59, p<0.01), as
well as the current use of olanzapine and haloperidol, were
associated with dose-dependent risk ratios for pneumonia
greater than 2.50. Furthermore, pneumonia had a longer
duration in these patients during the period of exposure to
each of these drugs (151).
With antidepressants, no increased risk of pneumonia
has been found in most studies (e.g., 158) (Table 2).
There seems to be no significant association between
mood stabilizers and pneumonia, and lithium even has a
dose-dependent protective effect (152) (Table 2). However,
the combination of mood stabilizers and SGAs or FGAs
was associated with an increased risk. Among drug combinations, olanzapine plus carbamazepine had the highest
risk (ARR 5 11.88, p<0.01), followed by clozapine plus valproic acid (RR 5 4.80, p<0.001) (152).
Although the possible mechanisms of drug-induced pneumonia remain speculative (153), H1 antagonism by clozapine
and olanzapine, inducing sedation, and M1 antagonism,
inducing dryness of the mouth, esophageal dilatation and
hypomotility, may be involved, as well as the additive sedating
effect by carbamazepine or valproic acid (152).

GASTROINTESTINAL DISEASES
Liver diseases
Liver function test abnormalities in patients receiving antipsychotics are common, but often mild and transient.
According to a systematic review (159), the median percentage of patients with any abnormal liver function test on any
antipsychotic was 32% (range: 5-78%). However, the median
percentage of patients with clinically significant elevations
(i.e., > 3-fold above the upper limit of normal for alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl
transpeptidase or > 2-fold the upper limit of normal for alkaline phosphatase) was 4% (range: 0-15%) (Table 2). Abnormalities were generally asymptomatic, arose within 6 weeks
of starting an antipsychotic, and did not worsen or resolved
with continued treatment. The most commonly abnormal liver function test involved transaminases, and there was no
clear difference between FGAs and SGAs.
Rarely, antipsychotics have been associated with severe
or fatal hepatic injury. The FGA chlorpromazine has been
most widely implicated with severe cholestatic hepatic injury. There are three main mechanisms by which antipsychotics can be associated with liver injury: by impairing bile
secretion, leading to cholestasis; by exerting a direct toxic
effect on hepatocytes; and by affecting the liver indirectly
via obesity leading to non-alcoholic fatty liver disease (159).
Between 0.5 and 3% of patients receiving antidepressants
may develop asymptomatic mild elevation of serum aminotransferase levels. However, all antidepressants can induce
hepatotoxicity, especially in elderly patients and those on
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polypharmacy (Table 2). The antidepressants with the highest risk of hepatotoxicity include iproniazid, nefazodone,
phenelzine, venlafaxine, imipramine, amitriptyline, duloxetine, bupropion, trazodone, tianeptine and agomelatine
(160-162). Those with the least potential include citalopram, escitalopram, paroxetine and fluvoxamine (162).
Monitoring of liver function tests and immediate discontinuation upon emergence of abnormal laboratory findings or
signs/symptoms of liver dysfunction are crucial, since most
cases of hepatic damage are reversible when detected early
(162).
Among mood stabilizers, carbamazepine and valproate
have been associated with liver dysfunction and should be
avoided in patients with pre-existing liver disease (163)
(Table 2).

Constipation
Severe constipation leading to serious consequences
and even death can occur with certain antipsychotics. The
most reported complications are paralytic ileus, faecal
impaction, bowel obstruction and intestine/bowel perforations (164).
Constipation has been most widely reported with clozapine (123,164), although it can be associated with other
antipsychotics as well (165) (Table 2). The prevalence of
constipation in randomized controlled trials is 39.6% with
zotepine, 21.3% with clozapine, 14.6% with haloperidol
and 12% with risperidone (166).
Constipation is a common side effect of tricyclic antidepressants, while it is not particularly associated with exposure to mood stabilizers (Table 2).

HAEMATOLOGIC DISEASES
Leucocytopenia and agranulocytosis
Antipsychotics (especially but not only clozapine), antidepressants (e.g., clomipramine and imipramine) and mood stabilizers (especially carbamazepine) have been associated with
leucocytopenia and agranulocytosis (167-170) (Table 2).
Clozapine (particularly in the first three months of treatment) and phenothiazines are the most common causes of
drug-related neutropenia/agranulocytosis (169). The risk
for neutropenia and agranulocytosis with clozapine is
approximately 3% and 1%, respectively, with older patients
being at higher risk (167,168). Carbamazepine should not
be used in combination with clozapine, due to its potentiation of neutropenia and agranulocytosis (169,170). Antiinfective agents, proton pump inhibitors and other gastrointestinal agents have also been associated with haematological adverse effects when co-prescribed with clozapine
(171). Non-tricyclic antidepressants are rarely associated
with agranulocytosis.
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With appropriate management, the mortality from druginduced agranulocytosis in Western countries is currently
approximately 5% (decreasing from 10-16% over the past
two decades) (167).

Thrombocytopenia
Among the reviewed psychotropic drug classes, only valproate has been associated with thrombocytopenia to a relevant degree (Table 2). The incidence may be around 5%,
and more likely at valproate serum levels above 80 mcg/ml,
especially in females and older people (172).

NEOPLASMS
Breast cancer
Generally, patients with SMI, especially schizophrenia,
have lower cancer rates than the general population (173),
despite unhealthy lifestyle and a higher likelihood of obesity. However, this comparison is complicated by the fact
that most cancers accumulate with age and that people
with SMI die on average 15-25 years earlier than the general population (11).
Breast cancer is one of the most commonly diagnosed
cancers worldwide (one in eight women will be diagnosed
with this cancer during their lifetime), is the leading cause of
cancer death among females, and starts occurring in early
adulthood (174-176). Given that women with schizophrenia have lower parity (177,178) and higher frequencies of
other known breast cancer risk factors (obesity, DM,
unhealthy lifestyle behaviors, including alcohol dependence
and smoking), one would anticipate higher breast cancer
rates in this population. However, data are conflicting.
Although several studies have shown an increased breast
cancer risk and mortality rate among women with schizophrenia (e.g., 173,179-182), other studies have found a
decreased or a statistically non-significantly increased risk
(e.g., 183,184) (Table 2). A recent meta-analysis of observational studies in people with central nervous system disorders found that patients with schizophrenia showed a
higher co-occurrence of breast cancer (effect size 5 1.25;
95% CI: 1.10-1.42) (185).
Increasing experimental and epidemiological data point
to the influence of prolactin in mammary carcinogenesis
(186), raising questions about the possible relationship
between prolactin-raising antipsychotics and breast cancer
risk. The current evidence base, however, is very limited.
The majority of studies focused on patients treated with
FGAs (186), not finding an increased breast cancer risk. An
exception is the cohort study by Wang et al (187), in which
52,819 women on antipsychotic dopamine antagonists
were compared with 55,289 women who were not on
antipsychotics. The authors found that, compared with

non-users, women who used antipsychotic dopamine antagonists had a 16% greater risk (AHR 5 1.16, 95% CI:
1.07-1.26) of developing breast cancer, with a direct doseresponse relationship. As stated by the authors, the magnitude of the observed risk, although statistically significant,
was small in absolute terms (1,239 cases of breast cancer in
the user group versus 1,228 cases in the non-user group).
Furthermore, it was estimated that there is less than a 14%
chance that a dopamine antagonist user who develops
breast cancer does so on the basis of her antipsychotic use.
The authors therefore concluded that their findings “do not
warrant changes in patients’ antipsychotic medication regimens” (187, p. 1153).
Among SGAs, there has been concern that risperidone,
amisulpride and paliperidone, which have been associated
with hyperprolactinemia (188), may increase the risk of
breast cancer. However, so far, results indicate that these
compounds do not seem to increase this risk (189).
A systematic review (190), including 93 studies (in vitro,
animal and human studies) considering the effects of antipsychotics (FGAs 1 SGAs) on cancer development, found
that these medications as a class cannot be considered as a
risk factor for breast cancer in humans. Moreover, some
reports describe mechanisms of cancer protection with antipsychotics (or antidepressants) (186,191,192). For example,
it has been shown in vitro that (prolactin-elevating) phenothiazines may enhance the effect of tamoxifen, a first-line
adjuvant treatment for breast cancer patients, in human
breast cancer cells (193,194). Thus, to date, no robust evidence exists for an increased risk of breast cancer due to
antipsychotic-induced hyperprolactinemia (186,195).
As evidence suggest that SSRIs can increase circulating
prolactin above the accepted normal range (20 ng/ml in
men and 25 ng/ml in women) (196-198) via prolactin
releasing factors, such as vasoactive intestinal peptide and
oxytocin (188), antidepressant-related breast cancer risk
has been questioned. Overall, however, results do not
support the serotonin-mediated pathway for the prolactinbreast cancer hypothesis, irrespective of the type of antidepressant (198-200) (Table 2).

Prolactinoma
Although a pharmacovigilance study raised concern
about a possible association between prolactin-raising antipsychotics and prolactinomas (201), evidence for a causal
relationship is missing (Table 2). Potential reasons for the
observational association include a background rate of 510% of silent prolactinomas that are more likely detected
when elevated prolactin levels prompt brain imaging studies, and the potential misclassification of pituitary hypertrophy related to prolactin elevation due to antipsychotics as
prolactinoma (188). In patients with secreting prolactinomas and psychosis, the partial D2 agonist aripiprazole may
be particularly useful (202).
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MUSCULOSKELETAL DISEASES
Osteoporosis
Schizophrenia and bipolar disorder are associated with
lower bone mineral density (BMD) and higher prevalence
of osteoporosis compared to the general population (203206). The etiology of BMD loss in these patients is complicated (204,207). Risk factors related to patients’ lifestyle
(e.g., smoking, reduced physical activity, alcohol abuse, vitamin D and calcium deficiency, polydipsia) (203), as well as
use of antipsychotics (207,208), are likely to be involved.
Several reviews and meta-analyses (209-213) have reported
that (major) depression is also associated with low BMD
and increased fracture risk.
Although raised prolactin levels induced by antipsychotics have been associated with an increased risk of
osteoporosis (214) (Table 2), clinical data implicating antipsychotic-induced hyperprolactinemia as a possible major
risk factor for bone loss remain limited and contradictory
(203,204). One review (203) showed that 60% of the studies
examining the relationship between antipsychotic-induced
hyperprolactinemia and BMD loss found some effects of
hyperprolactinemia. However, samples and effects were
small, and only few studies were prospective. The increased
risk for bone loss induced by hyperprolactinemia is believed
to be mediated by hypogonadism (215), leading to abnormally low sex hormone levels, although some evidence
suggests direct effects of prolactin on human osteoblasts
(216).
Most studies and reviews (157,203,217-223) found significant increases in the risk of fractures (ORs between 1.2 and
2.6) associated with antipsychotics. Compared with SGAs,
a higher fracture risk was found for FGAs in some studies
(158,220,224), possibly due to extrapyramidal symptoms
causing gait disturbances and impairing mobility and balance, which are risk factors for falls (and, thus, fractures) in
older adults (107). However, other studies (105,219,225)
found no differences between FGAs and SGAs. Moreover,
it is also unclear whether individual SGAs differ in the risk
of falls/fractures (105,218,226).
Longitudinal, cross-sectional and prospective cohort
studies, as well as meta-analyses, suggest that antidepressants, particularly SSRIs, at therapeutic doses are associated
with decreased BMD and increased fracture risk, especially
in older adults (218,220-222,227-249) (Table 2). Reduced
BMD has also been found in young adults and children prescribed SSRIs (250,251). For SSRIs and tricyclic antidepressants, a growing excess risk of fractures has been reported
with increasing dose (227,233,235), although this effect
does not appear to be homogeneous across the whole class
of drugs (227). The increase in risk is highest during the early stages of treatment, with a dramatic increase after initiation, reaching a peak within one month for tricyclics and
eight months for SSRIs (228), decreasing towards baseline
following discontinuation (227,228).
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The most recent meta-analysis (237), which pooled results
from 13 qualifying cohort and case-control studies, found
that SSRIs were associated with a significantly increased risk
of fractures (RR 5 1.72, 95% CI: 1.51-1.95, p<0.001). This
increased risk was also observed in studies that adjusted for
depression (RR 5 1.74, 95% CI: 1.28-2.36, p<0.001) and for
BMD (RR 5 1.70, 95% CI: 1.28-2.25, p<0.001). Treatment
with SSRIs seems also to be associated with an increased
failure of bone implants, which suggests the need for careful
surgical treatment planning in SSRI users (252). The effect
of SSRIs on bone formation and resorption appears to be
governed by the activation of a number of 5-HT receptors on
osteoblasts and osteoclasts via endocrine, autocrine/paracrine and neuronal pathways (241,253,254).
Lithium is possibly associated with a reduced fracture
risk (255,256) (Table 2). Long-term treatment with valproate combined with low-dose SGAs may adversely affect
BMD in premenopausal women with bipolar disorder
(257). Finally, concomitant use of an opioid with one or several antipsychotics may also increase fracture risk in elderly
patients (258,259).

OTHER PHYSICAL DISEASES
Kidney diseases
Nephrotoxicity is a well-known side effect of lithium
(260) (Table 2). Acute renal failure has been described in
lithium intoxication (261), but the greatest concern is the
possible progression to end-stage renal disease during longterm use (262).
However, conflicting evidence concerning lithium’s effect on renal function exists. A systematic review (263),
investigating the effects of lithium on renal function in older
adults, and the largest and most recent meta-analysis to date
(40), screening nearly 6,000 publications on various aspects
of potential lithium toxicity in patients with depression or
bipolar disorder, both concluded that there is little evidence
for a clinically significant reduction in renal function in
most patients, and that the risk of end-stage renal failure is
low. These results are consistent with a former metaanalysis (264). Nevertheless, end-stage renal failure only
starts appearing in some patients after continuous treatment
for more than 15-20 years, whereas meta-analyses include
numerous patients treated for shorter periods (265). Moreover, several studies (266,267) on prolonged lithium treatment have suggested that the risk of renal end-stage failure
might not be that low.
According to the International Group for the Study of
Lithium-Treated Patients, approximately 25% of patients on
medium-term lithium therapy (<15 years), as well as most
patients on long-term lithium treatment (>15 years), develop some form of chronic lithium nephropathy (268). However, this condition manifests primarily as impaired urinary
concentration with or without polyuria, which generally has
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little clinical relevance. In contrast, patients with severe
polyuria are at increased risk for lithium intoxication due
to fluctuations in sodium levels. Effects of lithium intoxication range from minor tubular changes to acute tubular
necrosis, which generally is reversible upon removal of
excess amounts of lithium. Recurrent lithium intoxication,
however, is thought to promote progressive lithium nephropathy (269). Thus, regular lithium level monitoring may protect against acute and chronic renal failure, and should be
mandatory in long-term lithium-treated patients (269).

Movement disorders
In susceptible patients, chronic treatment with antipsychotics can lead to movement disorders, including tardive
dyskinesia, tardive dystonia and tardive akathisia (270)
(Table 2). Although SGAs seem to have a 5- to 6-fold
reduced risk for tardive dyskinesia compared to FGAs
(271,272), the risk is not zero. Moreover, older people (273)
and those with extrapyramidal symptoms or anticholinergic
use (271) are at elevated risk for tardive dyskinesia.
Antidepressants, lithium and valproate are generally not
associated with tardive dyskinesia (Table 2). Nevertheless,
tremor and myoclonus, which can occur with lithium and
valproate, respectively, can be mistaken for tardive dyskinesia. Moreover, movement disorders can also occur endogenously in patients with schizophrenia (274), and other
medications, such as metoclopramide (275), also carry a
risk for tardive dyskinesia.

Seizure disorders
All antipsychotics, especially clozapine, have the potential to reduce the seizure threshold (276,277). This effect is
generally not clinically relevant, but is dose-dependent and
rises sharply at clozapine doses of 500-600 mg/day, while
relationships with clozapine blood levels are less clear
(278). When seizures occur, this is not a reason to discontinue clozapine; rather, valproate should be added for seizure
prophylaxis (adjusting the clozapine dose as needed) (127).
Antidepressants can also lower the seizure risk threshold
(91,276), with intermediate epileptogenic potential for tricyclic antidepressants and lower epileptogenic potential for
bupropion (277), which is still contraindicated in people
with seizure disorders (Table 2). Being antiepileptic medications, valproate and carbamazepine reduce seizure risk,
while lithium, which at lower doses may even be protective
(279), can lead to seizures when reaching toxic levels.

CONCLUSIONS
Patients with SMI are at increased risk for physical diseases and related earlier mortality (11,280). Besides mental

illness-related factors, disparities in health care access and
utilization, and unhealthy lifestyle, psychotropic medications can contribute to the emergence or aggravation of
physical diseases. This review summarized recent evidence
for the effect of antipsychotics, antidepressants and mood
stabilizers on physical health/illness in patients with schizophrenia, major depression and bipolar disorder.
In general, adverse effects on physical health are greatest
with antipsychotics, followed by mood stabilizers, tricyclic
antidepressants and newer antidepressants. However, effects vary greatly among individual agents, and interactions
with underlying host factors are relevant. Higher dosages,
polypharmacy, and the treatment of vulnerable (e.g., old or
young) people seems to be associated with a greater effect
on most physical diseases.
Although antipsychotics have the greatest potential to
adversely affect physical health, it is important to note that
several large, nationwide studies providing generalizable
data have suggested that all-cause mortality is higher in
patients with schizophrenia not receiving antipsychotics
(4,281). Furthermore, clozapine (4), antidepressants (282),
and lithium (283), as well as antiepileptics (284), are associated with reduced mortality from suicide. Thus, the potential risks of antipsychotics, antidepressants and mood stabilizers need to be weighed against the risk of the psychiatric
disorders for which they are used and the lasting potential
benefits that these medications can produce.
Nevertheless, greater attention to the possible impact of
psychotropic medications on the physical health of people
with SMI can aid clinicians in selecting appropriate
treatments for individual patients whose medication-independent risk factors for specific disorders require special
consideration. Moreover, knowledge about specific medication effects can help implementing appropriate monitoring
and management strategies aimed at improving physical
and well as mental health outcomes of these generally disadvantaged populations.
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